[HTML][HTML] Best practices for bioinformatic characterization of neoantigens for clinical utility
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
[引用][C] Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell, WE Gillanders… - Genome Medicine, 2019 - cir.nii.ac.jp
Best practices for bioinformatic characterization of neoantigens for clinical utility.
MM Richters, H Xia, KM Campbell… - Genome …, 2019 - search.ebscohost.com
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
[引用][C] Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell… - Genome Medicine …, 2019 - jglobal.jst.go.jp
Trends Cancer Res; Immune response to cancer therapy: mounting an effective antitumor
response and mechanisms of resistance; TR Medler, T Cotechini, LM Coussens; 1; 2015; 66 …
response and mechanisms of resistance; TR Medler, T Cotechini, LM Coussens; 1; 2015; 66 …
Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell, WE Gillanders… - 2019 - digitalcommons.wustl.edu
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumorspecific T cell recognition. Recently, researchers and clinicians have …
inducing tumorspecific T cell recognition. Recently, researchers and clinicians have …
Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell… - Genome …, 2019 - search.proquest.com
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell… - Genome …, 2019 - pubmed.ncbi.nlm.nih.gov
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell… - Genome …, 2019 - profiles.wustl.edu
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
[HTML][HTML] Best practices for bioinformatic characterization of neoantigens for clinical utility
MM Richters, H Xia, KM Campbell… - Genome …, 2019 - ncbi.nlm.nih.gov
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
Best practices for bioinformatic characterization of neoantigens for clinical utility.
MM Richters, H Xia, KM Campbell… - Genome …, 2019 - europepmc.org
Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …